Anti-platelet therapy: Is it all over in peripheral artery disease?

A. S. Jaipersad; Stanley H. Silverman; Gregory Y. H. Lip

doi:10.1160/TH10-01-0053

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 2010; 103(04): 689-691
DOI: 10.1160/TH10-01-0053

Editorial Focus

Schattauer GmbH

Anti-platelet therapy: Is it all over in peripheral artery disease?

Authors

A. S. Jaipersad

¹University of Birmingham Centre for Cardiovascular Sciences, City Hospital, Birmingham, UK

²Department of Vascular Surgery, City Hospital, Birmingham, UK
Stanley H. Silverman

²Department of Vascular Surgery, City Hospital, Birmingham, UK
Gregory Y. H. Lip

¹University of Birmingham Centre for Cardiovascular Sciences, City Hospital, Birmingham, UK

Abstract

Full Text

References

References
1 Bennett PC, Silverman S, Gill PS. et al. Ethnicity and peripheral artery disease. Q J Med 2009; 102: 3-16.
2 Anand S, Yusuf S, Xie C. et al. The Warfarin Antiplatelet Vascular Evaluation Trial Investigators. Oral Anticoagulation and Antiplatelet Therapy and Peripheral Artery Disease. N Engl J Med 2007; 357: 217-227.
3 Steffen LM, Duprez DA, Boucher L. et al. Management of Peripheral Artery Disease. Diabetes Spectrum 2008; 21: 171-177.
4 Newman AB, Shemanski L, Manolio TA. Ankle-arm index as a predictor of cardiovascular disease and mortality in the Cardiovascular Health Study. Arterioscler Thromb Vasc Biol 1999; 19: 538-545.
5 Heald CL, Fowkes FG, Murray GD. et al. Ankle Brachial Index Collaboration: Risk of mortality and cardiovascular disease associated with ankle brachial index: systematic review. Atherosclerosis 2006; 189: 61-69.
6 Leng GC, Fowkes FGR, Lee AJ. Use of ankle brachial pressure index to predict cardiovascular events and death: a cohort study. Br Med J 1996; 313: 1440-1444.
7 Sodhi HS, Shrestha SK, Rauniyar R. et al. Prevalence of peripheral arterial disease by ankle-brachial index and its correlation with carotid intimal thickness and coronary risk factors in Nepalese population over the age of forty years. Kathmandu Univ Med J 2007; 05: 12-15.
8 Ridker PM, Cushman M, Stampfer MJ. et al. Plasma concentrations of C-reactive protein and risk of developing peripheral vascular disease. Circulation 1998; 97: 425-428.
9 Smyth SS, Mcever RP, Weyrich AS. et al. Platelet function beyond hemostasis. Thromb Haemost 2009; 07: 1759-1766.
10 Dieter RS, Chu WW, Pacanowski JP. et al. The significance of lower extremity peripheral artery disease. Clin Cardiol 2002; 25: 3-10.
11 Holm T, Damås JK, Holven K. et al. CXC-chemokines in coronary artery disease: possible pathogenic role of interactions between oxidized low-density lipoprotein, platelets and peripheral blood mononuclear cells. Thromb Haemost 2003; 01: 257-262.
12 Falconer TM, Eikelboom JW, Hankey GJ. et al. Management of peripheral arterial disease in the elderly:focus on cilostazol. Clin Interv Aging 2008; 03: 17-23.
13 Davi G, Gresele P, Violi F. Diabetes mellitus, hyper-cholesterolemia, and hypertension but vascular disease per se are associated with persistent platelet activation in vivo. Evidence derived from the study of peripheral arterial disease. Circulation 1997; 96: 69-75.
14 Hohlfeld T, Zimmermann N, Weber AA. et al. Pyrazolinone analgesics prevent the antiplatelet effect of aspirin and preserve human platelet thromboxane synthesis. Thromb Haemost 2007; 06: 166-173.
15 Blann AD, Tan KT, Tayebjee MH. et al. Soluble CD40L in peripheral artery disease. Relationship with disease severity, platelet markers and the effects of angioplasty. Thromb Haemost 2005; 93: 578-583.
16 Bennett PC, Silverman S, Gill PS. et al. Peripheral arterial disease and Virchow’s triad. Thromb Haemost 2009; 101: 1032-1040.
17 Peace AJ, Tedesco AF, Foley DP. et al. Dual antiplatelet therapy unmasks distinct platelet reactivity in patients with coronary artery disease. Thromb Haemost 2008; 06: 2027-2034.
18 Ramcharan AS, Van Stralen KJ, Snoep JD. et al. HMG-CoA reductase inhibitors, other lipid-lowering medication, antiplatelet therapy, and the risk of venous thrombosis. Thromb Haemost 2008; 07: 514-520.
19 Basili S, Raparelli V, Vestri A. et al. Comparison of Efficacy of Antiplatelet Treatments for patients with claudication: A Meta-Analysis. Thromb Haemost 2010; 103: 766-773.
20 Murabito JM, D’Agostino RB, Silberhatz H. et al. Intermittent Claudication: a risk profile from the Framingham Heart Study. Circulation 1997; 96: 44-49.
21 Baigent C, Blackwell L, Collins R. et al. Antithrombotic Trialists’ (ATT) Collaboration. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009; 373: 1849-1860.
22 Berger JS, Krantz MJ, Kittelson JM. et al. Aspirin for the prevention of cardiovascular events in patients with peripheral artery disease. A Meta-analysis of randomized trials. J Am Med Assoc 2009; 301: 1909-1919.
23 Belch J, MacCuish A, Campbell I. et al. Prevention of Progression of Arterial Disease and Diabetes Study Group; Diabetes Registry Group; Royal College of Physicians Edinburgh. The Prevention of Progression of Arterial Disease and Diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. Br Med J 2008; 337: 1840.
24 McDermott MM, Criqui MH. Aspirin and Secondary Prevention in Peripheral Artery Disease. A perspective for the Early 21^st Century. J Am Med Assoc 2009; 301: 1927-1928.
25 CAPRIE Steering Committee.. A Randomized, blinded trial of Clopidogrel vs Aspirin in Patients at Risk of Ischemic Events (CAPRIE). Lancet 1996; 348: 1329-1339.
26 Cacoub PP, Bhatt DL, Steg PG. et al. CHARISMA Investigators. Patients with peripheral arterial disease in the CHARISMA trial. Eur Heart J 2009; 30: 192-201.
27 Ogawa H, Nakayama M, Morimoto T. et al. Low-Dose Aspirin for Primary Prevention of Athero-sclerotic Events in Patients with Type 2 Diabetes. A Randomized Controlled Trial. J Am Med Assoc 2008; 300: 2134-2141.
28 Lowry F. Aspirin for Asymptomatic Atherosclerosis (AAA) trialists. [Internet] European Society of Cardiology (ESC) 2009 Congress; Aug. 2009 Available from: http://www.theheart.org/ar ticle/996383.do
29 Dixon BS. DAC Study Group.. The Effect of Dipyridamole plus Aspirin on Hemodialysis Graft Paten-cy. N Engl J Med 2009; 360: 2191-2201.
30 Catalano M, Born G, Peto R. Critical Leg Ischaemia Prevention Study (CLIPS) Group. Prevention of serious vascular events by aspirin amongst patients with peripheral arterial disease: randomized, double-blind trial. J Intern Med 2007; 261: 276-284.
31 Gresele P, Migliacci R. The peripheral arterial disease subgroup in the CHARISMA trial; does it tell us anything new?. European Heart J 2009; 30: 131-132.
32 Bounameaux H. Intermittent claudication: how should we react to this symptom?. Eur Heart J 2002; 23: 1002-1004.